Elicio publishes Phase 1 ELI-002 data in Nature Medicine: OS 28.94 months, 77% risk reduction

Elicio Therapeutics, Inc.

At 19.7 mo median follow-up, median OS increased to 28.94 months from 16.33 months in Phase 1 AMPLIFY-201.
Above-threshold T cell responses gave 77% reduction in death risk (HR 0.23) and 88% reduction in relapse risk (HR 0.12).
84% (21/25) of patients had tumor biomarker responses; 24% (6/25) achieved complete biomarker clearance.
Final event-driven DFS analysis for Phase 2 AMPLIFY-7P study of ELI-002 7P in PDAC anticipated Q4 2025.
ELI-002 was well tolerated; no dose-limiting toxicities or ≥Grade 3 treatment-related adverse events observed.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.